Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Novartis | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Novartis

Pharmaceutical sales up 2%

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novartis

1Q Revenues: $13.7 billion (-2%)

1Q Earnings: $3.1 billion (-8%)

Comments: Pharmaceutical sales were up 2% to $7.8 billion, driven by Lucentis, Tasigna, Afinitor and Gilenya, which now represent 33% of division sales compared to 26% in 1Q11. Alcon sales were up 5% to $2.5 billion driven by surgical and ophthalmics. Sandoz sales declined 10% to $2.1 billion mainly due to increased competition for enoxaparin, while volume growth was flat. Vaccines and Diagnostics sales were down 19% to $299.0 million mainly due to an exceptionally strong 1Q11. Consumer Health sales dropped 20% to $932 million, impacted by the suspension of production at the Lincoln site.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters